Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design |
| |
Authors: | Wyatt Paul G Woodhead Andrew J Berdini Valerio Boulstridge John A Carr Maria G Cross David M Davis Deborah J Devine Lindsay A Early Theresa R Feltell Ruth E Lewis E Jonathan McMenamin Rachel L Navarro Eva F O'Brien Michael A O'Reilly Marc Reule Matthias Saxty Gordon Seavers Lisa C A Smith Donna-Michelle Squires Matt S Trewartha Gary Walker Margaret T Woolford Alison J-A |
| |
Affiliation: | Astex Therapeutics Ltd, 436 Cambridge Science Park, Milton Road, Cambridge, CB4 0QA, United Kingdom. p.g.wyatt@dundee.ac.uk |
| |
Abstract: | The application of fragment-based screening techniques to cyclin dependent kinase 2 (CDK2) identified multiple (>30) efficient, synthetically tractable small molecule hits for further optimization. Structure-based design approaches led to the identification of multiple lead series, which retained the key interactions of the initial binding fragments and additionally explored other areas of the ATP binding site. The majority of this paper details the structure-guided optimization of indazole (6) using information gained from multiple ligand-CDK2 cocrystal structures. Identification of key binding features for this class of compounds resulted in a series of molecules with low nM affinity for CDK2. Optimisation of cellular activity and characterization of pharmacokinetic properties led to the identification of 33 (AT7519), which is currently being evaluated in clinical trials for the treatment of human cancers. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|